From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?
Open Access
- 30 June 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (11) , 1434-1444
Abstract
The most common type of primary brain tumor is malignant glioma. Despite intensive therapeutic efforts, the majority of these neoplasms remain incurable. Imaging techniques are important for initial tumor detection and comprise indispensable tools for monitoring treatment. Structural imaging using contrast-enhanced MRI is the method of choice for brain tumor surveillance, but its capacity to differentiate tumor from nonspecific tissue changes can be limited, particularly with posttreatment gliomas. Metabolic imaging using positron-emission-tomography (PET) can provide relevant additional information, which may allow for better assessment of tumor burden in ambiguous cases. Specific PET tracers have addressed numerous molecular targets in the last decades, but only a few have achieved relevance in routine clinical practice. At present, PET studies using radiolabeled amino acids appear to improve clinical decision-making as these tracers can offer better delineation of tumor extent as well as improved targeting of biopsies, surgical interventions, and radiation therapy. Amino acid PET imaging also appears useful for distinguishing glioma recurrence or progression from postradiation treatment effects, particularly radiation necrosis and pseudoprogression, and provides information on histological grading and patient prognosis. In the last decade, the tracers O-(2-[18F]fluoroethyl)-L-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) have been increasingly used for these indications. This review article focuses on these tracers and summarizes their recent applications for patients with brain tumors. Current uses of tracers other than FET and FDOPA are also discussed, and the most frequent practical questions regarding PET brain tumor imaging are reviewed.Keywords
This publication has 108 references indexed in Scilit:
- [11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approachesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Discrepant MR and [18F]Fluoroethyl-l-Tyrosine PET Imaging Findings in a Patient with Bevacizumab FailureCase Reports in Oncology, 2012
- Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosisRadiation Oncology, 2011
- Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomasNeuro-Oncology, 2011
- Advanced MRI and PET imaging for assessment of treatment response in patients with gliomasThe Lancet Neurology, 2010
- Pseudoprogression and pseudoresponse in the treatment of gliomasCurrent Opinion in Neurology, 2009
- Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparisonRadiation Oncology, 2009
- [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade gliomaRadiation Oncology, 2008
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005